The reimbursement decision comes after the adrenaline-based nasal spray was approved by the TGA earlier this year.
The anaphylaxis world has started the new financial year with a bang.
From 1 July 2026, the adrenaline-based nasal spray neffy is available via the PBS for the treatment of anaphylaxis in adults and children aged four years or older who weigh at least 15kg.
Professor Connie Katelaris AM, National Allergy Centre of Excellence interim Respiratory Allergy Stream Co-chair, said the reimbursement decision was an important outcome for Australians who were at risk of anaphylaxis.
“Previously only available as private prescription, PBS listing of neffy gives more Australian patients the ability to access neffy should this be their preferred adrenaline device for the emergency treatment of anaphylaxis,” the NSW-based allergist said in a statement.
“Anaphylaxis is a difficult condition to manage and the availability of subsidised adrenaline options means Australians living with anaphylaxis and their doctors have more choice in treatment options.”
Maria Said AM, health strategy and advocacy manager at Allergy & Anaphylaxis Australia, highlighted the day-to-day impact that the risk of anaphylaxis could have on an individual’s life.
“For people who are at risk of anaphylaxis, everyday activities that many Australians take for granted often require careful planning and constant vigilance,” said Ms Said.
“Whether it’s eating at restaurants, attending social events or travelling, those living with the risk of anaphylaxis are frequently thinking ahead about how to stay safe and what they would do in an emergency.
“For parents and carers of children at risk of anaphylaxis, experiences such as play dates, parties and school excursions require additional planning and preparation.
“People living with severe allergies know that there is no one-size-fits-all approach to managing anaphylaxis. The reimbursement of a treatment option that does not require injection provides patients with more choice to determine what may work best for them.”
Related
Claire Morgan, senior medical director of pharmaceuticals at CSL Seqirus – the company that produces neffy – was understandably positive about the decision.
“We are pleased that eligible Australians will now have subsidised access to this treatment option and acknowledge the valuable contribution of healthcare professionals, patient advocacy organisations and professional bodies in supporting the allergy community,” Ms Morgan told media.
neffy was approved by the TGA for use in individuals aged four years or older in February 2026. It is the only adrenaline nasal spray approved in the country.
Adrenaline remains the first-line treatment of anaphylaxis, where it reverses airway obstruction, reduces mucosal oedema, and supports cardiovascular function.
Australia has one of the highest rates of anaphylaxis in the world. Public hospitals reporting a 51% increase in anaphylaxis-related ED presentations and a 35% increase in anaphylaxis-related hospital admissions between 2015 and 2020, according to data from the Australian Commission on Safety and Quality in Healthcare and the Australasian Society of Clinical Immunology and Allergy.
